Study to Evaluate Analgesic Effect of IV Administration of Kappa Agonist CR845 For Hysterectomy Surgery

NCT ID: NCT01361568

Last Updated: 2014-05-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 203 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-07-31
• Study Completion Date: 2012-04-30

Brief Summary

The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.

Detailed Description

Currently, the most widely used drugs to treat pain after surgery are opiates, such as morphine. Morphine works mainly by activating one of several types of opiate receptors that control some of our pain sensation - the so-called mu opiate receptors. These receptors are located in many areas of the brain and also outside of the brain. By activating these receptors, morphine provides significant pain relief, but also causes side effects that limit its use. Some of these side effects include: respiratory depression or arrest (slowed or stopped breathing), sedation (a state of calmness or extreme relaxation), euphoria (an exaggerated feeling of physical and mental well-being), constipation, nausea, vomiting, and drug addiction.

In order to avoid the side effects of morphine and other mu opiates, the present experimental drug CR845 was designed to work at a different type of opiate receptor - called kappa - that can also provide pain relief, by acting on sensory nerves outside the brain. CR845 was designed to penetrate the brain much less than other opiate drugs, which should result in pain relief similar to that of morphine, but with fewer side effects. Because CR845 activates kappa receptors instead of mu receptors, the side effects are different than with a morphine-type drug. In particular, kappa opiates, such as CR845, do not cause respiratory depression or arrest, euphoria, constipation, drug tolerance, physical drug dependence or drug addiction. For these reasons, CR845 may present a distinct advantage over other opiates that are currently used for pain relief and post-operative pain in particular.

Conditions

Postoperative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

CR845

Peripheral kappa opioid receptor agonist

Group Type: EXPERIMENTAL

CR845

Intervention Type: DRUG

Single i.v. dose (0.04 mg/kg) administered preoperatively

CR845

Intervention Type: DRUG

Single i.v. dose (0.04 mg/kg) administered postoperatively for pain

Placebo

Matched Placebo

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Single i.v. dose administered preoperatively

Placebo

Intervention Type: DRUG

Single i.v. dose administered postoperatively for pain

Interventions

CR845

Single i.v. dose (0.04 mg/kg) administered preoperatively

Intervention Type: DRUG

Placebo

Single i.v. dose administered preoperatively

Intervention Type: DRUG

CR845

Single i.v. dose (0.04 mg/kg) administered postoperatively for pain

Intervention Type: DRUG

Placebo

Single i.v. dose administered postoperatively for pain

Intervention Type: DRUG

Other Intervention Names

Preoperative Active Dose; Preoperative Placebo Dose; Postoperative Active for Pain; Postoperative Placebo for Pain

Eligibility Criteria

Inclusion Criteria

• Able to provide written informed consent prior to any study procedures;
• Able to communicate clearly with the Investigator and staff;
• Female between 21 and 65 years of age, inclusive;
• Scheduled for elective laparoscopic hysterectomy under general anesthesia;
• Negative result on serum pregnancy test at screening and negative urine pregnancy test at Baseline (for women of child-bearing potential only) and not currently breast feeding, or planning to do so within 30 days of dosing;
• Negative urine drug screen for drugs of abuse at Screening and at Baseline;
• American Society of Anesthesiologists (ASA) risk class of I to III;
• Body mass index (BMI) between 17 and 40 inclusive.

Exclusion Criteria

• Has known allergies to opioids, or hypersensitivity to other materials (such as infusion line) or medications to be used in the study;
• Has a known or suspected history of Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)-diagnosed alcohol, opiate or other drug abuse or dependence within 12 months prior to screening;
• Is unable to refrain from alcohol consumption for a period beginning 24 hours prior to surgery through the end of the Treatment Period;
• Is scheduled to undergo a hysterectomy that will utilize any type of robotic technology and/or a concomitant surgical procedure that would produce a significantly greater degree of surgical trauma than the laparoscopic hysterectomy or laparoscopic assisted vaginal hysterectomy alone;
• Has taken non-opioid analgesics (including cyclooxygenase-2 [COX-2] inhibitors) or nonsteroidal anti-inflammatory drugs (NSAIDs) within 12 hours of the Baseline assessments;
• Has taken any opioid analgesics or used systemic steroids within 4 days of surgery OR has previously used opiates chronically for a period of ≥3 months;
• Has used antipsychotics, antiepileptics, sedatives, hypnotics, or antianxiety agents, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants for < 30 days prior to surgery or had a dose change within the previous 30 days;
• Has taken any prescription or over-the-counter medication within 3 days prior to surgery that, in the opinion of the Investigator, is expected to confound the analgesic response;
• Has taken herbal agents or nutraceuticals (i.e., chaparral, comfrey, germander, gin bu huan, kava, pennyroyal, skullcap, St. John's wort, or valerian) 7 days prior to surgery;
• In the opinion of Investigator shows clinical signs of hypovolemia;
• Has an oxygen saturation < 92% on room air at Screening or prior to receiving the first infusion of study drug;
• Has any history of clinically significant cardiovascular disease,
• Has a clinically significant abnormal electrocardiogram (ECG) or a history of additional risk factors for torsades de pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome);
• Has a history of any serious medical conditions that in the opinion of the Investigator would preclude study participation;
• Has serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, or gamma glutamyl transferase (GGT) >2.5 x the upper limit of normal (ULN) at screening;
• Has bilirubin, blood urea nitrogen (BUN), or creatinine >1.5 x the reference ULN at Screening;
• Has abnormally low hemoglobin < 10 mg/dl at Screening;
• Has serum sodium levels > 146 mmol/L at Screening;
• Has impaired renal function (creatinine clearance [CrCl] < 50 ml/min) at Screening;
• Has a positive test for human immunodeficiency virus (HIV) or known history of HIV infection;
• Has received another investigational drug within 30 days of scheduled surgery;
• Has a significant chronic pain condition in areas unrelated to the operative site at the time of Screening that in the Investigator's opinion could confound the interpretation of study results

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: FEMALE
• Accepts Healthy Volunteers: No

Sponsors

Cara Therapeutics, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tong-Joo Gan, MD, MHS

Role: PRINCIPAL_INVESTIGATOR

Duke University

Locations

Shoals Clinical Research Associates

Florence, Alabama, United States

Horizon Research Group

Mobile, Alabama, United States

Wilmax

Mobile, Alabama, United States

Drug Research and Analysis Corp

Montgomery, Alabama, United States

Shoals Medical Trials, INC

Sheffield, Alabama, United States

Precision Clinical Trials

Phoenix, Arizona, United States

Woodland Healthcare California Clinical Research, Inc

Davis, California, United States

Olive View-UCLA Medical Center

Sylmar, California, United States

Visions Clinical Research

Boynton Beach, Florida, United States

Riverside Clinical Research

Edgewater, Florida, United States

University of Miami, Dept of

Miami, Florida, United States

Cypress Medical Research

Wichita, Kansas, United States

Cooper University Hospital

Camden, New Jersey, United States

Duke University

Durham, North Carolina, United States

Ohio State University Medical, Dept of Anesthesia

Columbus, Ohio, United States

Palmetto Clinical Research,

Greenville, South Carolina, United States

Chattanooga Medical Research

Chattanooga, Tennessee, United States

Texas Health Care, PLLC

Fort Worth, Texas, United States

Countries

United States

Other Identifiers

CR845 CLIN2002

Identifier Type: -

Identifier Source: org_study_id